Sarcoma includes cancers of muscle, bone and soft tissues.

The Sarcoma Disease Site Group (Sarcoma DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Reports produced by this group are available below.

• Doxorubicin-based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma
  11-1 PG: July 2004 Update
  
  • Summary
  • Summary & Full Report
• Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults
  11-2 PG: February 2005 Update
  
  • Summary
  • Summary & Full Report
• Ifosfamide-based Combination Chemotherapy in Advanced Soft Tissue Sarcoma
  11-4 EBS: April 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in the First-line Treatment of Advanced or Metastatic Adult Soft Tissue Sarcoma
  11-5 EBS: April 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Imatinib Mesylate (GleevecTM) for the Treatment of Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumours
  11-7 EBS: April 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients
  11-8 EBS: June 2009
  
  • Practice Guideline
  • Evidence-Based Series